Patient group
Erwachsene mit mittelschwerer bis schwerer aktiver Hidradenitis suppurativa (HS), die unzureichend auf eine konventionelle systemische HS-Therapie ansprechen
completed2023-06-15D series
Secukinumab
Neues Anwendungsgebiet: Hidradenitis suppurativa (Acne inversa
Open official case page ↗
- Brand
- Cosentyx
- Manufacturer
- Novartis Pharma GmbH
G-BA action
final resolution
2023-12-07
Arzneimittel-Richtlinie/Anlage XII: Secukinumab (Neues Anwendungsgebiet: Hidradenitis suppurativa (Acne inversa))
Evidence-checked summary
The G-BA found no proven added benefit for Erwachsene mit mittelschwerer bis schwerer aktiver Hidradenitis suppurativa (HS), die unzureichend auf eine konventionelle systemische HS-Therapie ansprechen. The appropriate comparator was Adalimumab. The G-BA issued a final resolution on 2023-12-07. The official page states that it took effect as follows: 07.12.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2023-10-23
31 parsed turns
Oral hearing: Secukinumab (Neues Anwendungsgebiet: Hidradenitis suppurativa (Acne inversa))
Official Wortprotokoll · 7 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A23-51
matched
Secukinumab (hidradenitis suppurativa) – Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 44 pages
G-BA decisions
Distinct actions and documents
2023-12-07
final resolution
Arzneimittel-Richtlinie/Anlage XII: Secukinumab (Neues Anwendungsgebiet: Hidradenitis suppurativa (Acne inversa))
The G-BA found no proven added benefit for Erwachsene mit mittelschwerer bis schwerer aktiver Hidradenitis suppurativa (HS), die unzureichend auf eine konventionelle systemische HS-Therapie ansprechen. The appropriate comparator was Adalimumab. The G-BA issued a final resolution on 2023-12-07. The official page states that it took effect as follows: 07.12.2023. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗comparator informationInformationen zur zweckmäßigen VergleichstherapieOpen ↗annex xii current versionSecukinumabOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗iqwig assessmentNutzenbewertung IQWiGOpen ↗
Generic graph relations · 5
HAS ASSESSMENTSecukinumabHAS ASSOCIATED DECISIONArzneimittel-Richtlinie/Anlage XII: Secukinumab (Neues Anwendungsgebiet: Hidradenitis suppurativa (Acne inversa))HAS HEARINGOral hearing: Secukinumab (Neues Anwendungsgebiet: Hidradenitis suppurativa (Acne inversa))OWNS DOCUMENTInformationen zur zweckmäßigen VergleichstherapieOWNS DOCUMENTSecukinumab